Wire · opportunities
Regulatory path for spatial assays as diagnostics
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 August 2026 · Fusion42 review
An AI-powered digital pathology tool, ArteraAI Prostate, successfully navigated the FDA Breakthrough Device Designation to De Novo marketing authorization, setting a clear regulatory precedent for complex spatial assays as diagnostics. The FDA also facilitates platform updates via Predetermined Change Control Plans, accelerating cross-platform validation without repeated submissions.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You can use the FDA’s Breakthrough Device Program as a validated route for complex AI-powered diagnostics now. This opens the door to faster market entry if you shape your development to fit the program’s mechanisms from the start.
◆ Coverage
1 source · 19 Aug 2026
◆ Related on Wire
◆ Topics